Vector-containing medium harvested from murine packaging cell lines has been shown to contain factors which can negatively influence the transduction and maintenance of hematopoietic stem cells. Thus, we generated a human packaging cell line with a gibbon ape leukemia virus pseudotype (Phoenix-GALV), and we evaluated vectors produced by Phoenix-GALV for their ability to transduce hematopoietic progenitor / stem cells. In three baboons, we used a competitive repopulation assay to directly compare GALV-pseudotype retrovirus vectors produced by either Phoenix-GALV or by the NIH 3T3-derived packaging cell line, PG13. In three additional baboons we compared Phoenix-GALV-derived vectors to more recently developed lentiviral vectors. Gene transfer efficiency into hematopoietic repopulating cells was assessed by evaluating the number of genetically modified peripheral blood and marrow cells using flow cytometry and real-time PCR. Transduction efficiency into hematopoietic repopulating cells was significantly higher using the Phoenix-GALV-derived vector as compared to the PG13-derived vectors or lentiviral vectors, with stable transduction levels up to 25%. Two animals were followed for more than 1 year. Flow cytometric analysis of hematopoietic subpopulations in these animals revealed transgene expression in CD13 
Abstract
Vector-containing medium harvested from murine packaging cell lines has been shown to contain factors which can negatively influence the transduction and maintenance of hematopoietic stem cells. Thus, we generated a human packaging cell line with a gibbon ape leukemia virus pseudotype (Phoenix-GALV), and we evaluated vectors produced by Phoenix-GALV for their ability to transduce hematopoietic progenitor / stem cells. In three baboons, we used a competitive repopulation assay to directly compare GALV-pseudotype retrovirus vectors produced by either Phoenix-GALV or by the NIH 3T3-derived packaging cell line, PG13. In three additional baboons we compared Phoenix-GALV-derived vectors to more recently developed lentiviral vectors. Gene transfer efficiency into hematopoietic repopulating cells was assessed by evaluating the number of genetically modified peripheral blood and marrow cells using flow cytometry and real-time PCR. Transduction efficiency into hematopoietic repopulating cells was significantly higher using the Phoenix-GALV-derived vector as compared to the PG13-derived vectors or lentiviral vectors, with stable transduction levels up to 25%. Two animals were followed for more than 1 year. Flow cytometric analysis of hematopoietic subpopulations in these animals revealed transgene expression in CD13 + granulocytes, CD20 + B lymphocytes, CD3 + T lymphocytes, CD 61 + platelets, as well as red blood cells, indicating multilineage engraftment of cells transduced by Phoenix-GALV-pseudotype vectors. In addition, transduction efficiency into human CD34 + cells was significantly higher than transduction of baboon CD34 + cells, suggesting that Phoenix-GALV-derived oncoretroviral vectors may be even more efficient in human stem cell gene therapy applications.
Introduction
The potential of hematopoietic stem cell gene therapy has recently been demonstrated by the successful treatment of patients with severe combined immunodeficiency syndrome. 1 using retroviral vectors including their predominantly quiescent cell cycle state, 2 low viral receptor density, 3 and the requirement for relatively long ex vivo culture. 4 So far, most studies in humans and large animals have been performed using oncoretroviral vectors produced by mouse-derived packaging cells. Conditioned medium harvested from murine packaging cell lines has been shown to negatively affect the transduction efficiency of the target cells. Xu et al. showed that cytokines secreted by the producer cells play a role in the suppression of retrovirus transduction of human CD34 + cells. 5 Proteoglycans in the conditioned medium of mouse-derived NIH 3T3 packaging cells have also been shown to inhibit retroviral infection. 6, 7 To avoid these inhibitory factors, we constructed an oncoretroviral producer cell line based on human cells. We used 293 cells since these cells have been used for the production of high-titer vectors by many investigators and vectors produced by 293-based packaging cells have been shown to efficiently transduce hematopoietic cells. 8 We chose the gibbon ape leukemia
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From virus (GALV) as an envelope gene, which we previously reported to yield improved gene transfer into non-human primate HSC. 9 A limiting factor to efficient stem cell transduction is the quiescent nature of stem cells.
Oncoretroviral vectors require cell division to integrate into the host genome, and primitive stem cells are mostly quiescent. Lentiviral vectors based on the human immunodeficiency virus (HIV) genome have been shown to transduce nondividing cells 10, 11 and, thus, may be a superior vector system than oncoretroviral vectors for transduction of HSC. Efficient transduction of human nonobese diabetic/severe combined immune-deficient (NOD/SCID) mouse repopulating cells with lentiviral vectors has been reported with levels of up to 50%. 12, 13 In the current study, we examined gene transfer into baboon hematopoietic repopulating cells using Phoenix-GALV-pseudotyped vectors. We used a competitive repopulation assay in the baboon to directly compare Phoenix-GALV-pseudotyped vectors to PG13-pseudotyped vectors and to lentiviral vectors.
Materials and Methods

Construction of retrovirus packaging cell line Phoenix-GALV
The plasmid pMOV-GaLV Seato env (kindly provided by A. Packaging cell clones were rescreened for NGFR expression, and clones with high NGFR expression were transfected with the retroviral vector pMNDEGFPSN (kindly provided by D.
Kohn, Los Angeles, CA) to produce transient supernatant. Human CEMSS cells were transduced with retroviral supernatant and the transduction efficiency evaluated by flow cytometry 3 days after infection. The eight best clones were used to package pLZRSBMNEGFP, and supernatants were screened on human HT1080 cells and human CD34
+ peripheral blood cells. The packaging cell clone 100 was identified to produce the highest rate of gene transfer into all cell types and was therefore termed the packaging cell line Phoenix-GALV.
Oncoretrovirus vectors
The MNDEGFPSN and MNDEYFPSN vectors encode the enhanced green fluorescent protein 
Lentivirus vectors
The lentiviral transfer vector RRLsin.cPPT.hPGK.GFP.Wpre (kindly provided by L. Naldini, Torino, Italy) is a self-inactivating HIV-derived vector expressing the enhanced green fluorescent protein (EGFP) from the internal human phosphoglycerate kinase promoter (hPGK), Care and Use Committees. The autologous baboon transplants including all procedures were performed as previously described. 9, 14 Prior to bone marrow harvest, animals were treated with rh-SCF (50 µg/kg) and rh-G-CSF (100 µg/kg) (kindly provided by G. Molineux, Amgen, Thousand Oaks, CA) as single daily subcutaneous injections. After 5 days of growth factor administration, marrow (25 to 60 mL) was aspirated from the humeri and/or femora and collected in preservative-free heparin. In preparation for transplantation, all animals received myeloablative irradiation (TBI), 1,020 cGy, at 7 cGy/minute as two equally divided doses 24 hours apart. Animals in the present study were given posttransplant G-CSF, 100 µg/kg, intravenously, once daily starting at day 0 until their peripheral blood neutrophil counts were >1000/µL. 
Analysis of EGFP/EYFP expression in a CFU-C assay
CD34-enriched cells (1000 per 35-mm plate) were cultured at least in triplicate in a double-layer agar culture system as previously described. 14 Briefly, isolated cells were cultured in alpha minimal essential medium supplemented with 25% fetal bovine serum (FBS; Hyclone, Logan, UT), 0.1% bovine serum albumin (BSA; fraction V; Sigma, St. Louis, MO), 0.3% (wt/vol) agar (BioWhittacker, Rockland, ME) overlaid on medium with 0.5% agar (wt/vol) containing 100 ng/mL of SCF, IL-3, IL-6, GM-CSF, G-CSF and 4 U/mL Epo (provided by G. Molineux, Amgen, Thousand Oaks, CA). Cultures were incubated at 37°C in 5% CO 2 in a humidified incubator. Colonies were enumerated and evaluated for EGFP/EYFP expression at day 14 of culture using an inverted fluorescent microscope. cell. Reactions were run using the ABI master mix (Applied Biosystems, Branchburg, NJ) on the ABI Prism 7700 sequence detection system (Applied Biosystems) using the following thermal cycling conditions: 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
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Detection of helper virus
All animals were evaluated for generation of replication competent helper virus at up to three time points after transplantation. Peripheral blood mononuclear cell DNA was assayed for recombinant helper virus genomes by PCR using the primers and PCR conditions described previously. 9 
Results
Engraftment of transduced cells and follow-up
We used a competitive repopulation assay to study gene transfer into non-human primate repopulating cells using GALV-pseudotype oncoretroviral vectors produced by a human producer cell line (Phoenix-GALV). Six baboons were transplanted with transduced CD34-enriched autologous marrow cells to compare oncoretroviral vectors produced by Phoenix-GALV to oncoretroviral vectors produced by PG13 (three animals) or to lentiviral vectors (three animals) produced by transient transfection of 293T cells. A stable ANC >500/µL was reached at a median of 16.5 days (range [11] [12] [13] [14] [15] [16] [17] [18] [19] . Average follow-up in the animals is 37 weeks posttransplant.
Comparison between the Phoenix-GALV-and PG13-derived vectors
We first wished to directly compare vectors produced by Phoenix-GALV to vectors produced by PG13. CD34-enriched bone marrow cells were prestimulated and then divided into two equal fractions and transduced with either MNDEGFPSN (PG13) or MNDEYFPSN (Phoenix-GALV).
The mean expansion of cells during transduction was similar for the PG13-pseudotyped vector and the Phoenix-GALV-pseudotyped vector (2.4-vs. 2.6-fold).
Gene transfer rates into the bulk population of CD34-enriched cells were determined by flow cytometry on day 3 after the end of transduction (Table 1) . Gene transfer efficiency into these cells was significantly higher with the Phoenix-GALV-derived vector (average 20.1%)
than with the PG13-derived vector (average 6.9%, P < 0.02 by paired t-test). Gene transfer efficiency into colony forming cells within the same cell fractions was also determined by quantification of fluorescence-positive CFU-C ( Table 1 ). The overall gene transfer efficiency into CFUs was similar to the overall transduction rate as determined by flow cytometry. The use All animals studied were transplanted as outlined under Materials and Methods with oncoretroviral vectors pseudotyped by either Phoenix-GALV or PG13 as noted. Displayed are, for both vectors in each of the three animals, the percentage of fluorescence-positive cells in liquid culture three days after transduction and the percentage of fluorescence-positive colonies plated immediately after transduction.
† Follow-up on this animal was discontinued and it was transferred onto a different study. Phoenix-GALV = Phoenix-GALV/MNDEYFPSN; PG13 = PG13/MNDEGFPSN Growth factors used for this set of animals were SCF, G-CSF and MGDF at 100 ng/mL each.
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Comparison between Phoenix-GALV-derived oncoretroviral vectors and lentiviral vectors
In three additional animals, we compared Phoenix-GALV-derived vectors to lentiviral vectors.
We used a modified growth factor combination for the prestimulation and transduction based on our encouraging results using IL3, IL6, SCF, MGDF, Flt3-L, and G-CSF. 16 One-half of the cells was transduced with MNDEYFPSN (Phoenix-GALV) while the other half was transduced with the VSV-G-pseudotype lentiviral vector RRLsin.cPPT.hPGK.YFP.Wpre. Mean cell expansion during the transduction time was 4.2-fold, slightly higher than in the first set of animals, but there was no significant difference between the two experimental arms in each animal.
Gene transfer rates prior to reinfusion of the cells are shown in Table 2 . Gene transfer efficiency into these cells as determined by flow cytometry was significantly higher using the Phoenix-GALV-derived vector (average 38.4%) than with the lentiviral vector (average 18.5%, P = 0.04 by paired t-test). Gene transfer efficiency into CFUs was also higher using the Phoenix-GALV-derived vector as compared to the lentiviral vector (average 29.6% versus 16%). For personal use only. on October 3, 2017. by guest www.bloodjournal.org From at 3 to 6 months posttransplant, and marking/expression levels appear to have reached a plateau.
Transduction efficiency with the lentiviral vector was up to 2.4% at an early time point posttransplant and then decreased to levels around 1% after 2-3 months.
Gene expression in multiple hematopoietic lineages
To assess gene expression in different For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
Discussion
In the current study, we show in a non-human primate model highly efficient gene transfer into hematopoietic repopulating cells using a GALV-pseudotype oncoretroviral vector produced by the newly established human-derived producer cell line Phoenix-GALV. Up to 60% of hematopoietic repopulating cells were transduced early after transplant and up to 25% after transduction levels stabilized at 3 to 6 months. All animals had persistent marking and expression, suggesting that neither transcriptional transgene silencing nor immune responses to genetically modified cells occurred. In addition, the use of Phoenix-GALV-derived vectors resulted in significantly higher gene transfer into human CD34-enriched cells than PG13-derived vectors, emphasizing its potential for human stem cell gene therapy applications.
Murine-derived producer cell lines have been reported to produce inhibiting factors, which can negatively affect gene transfer and/or stem cell maintenance. 6, 17 More recently, conditioned medium from human HT1080 cells has also been described to have a negative, differentiating effect on the maintenance of NOD/SCID repopulating cells. 18 Such negative effects have not been reported with human packaging cells based on 293 cells. 8, 19, 20 Thus, we generated a GALV-pseudotype producer cell line based on the 293-derived Phoenix cells, and we evaluated the use of oncoretroviral vectors produced by Phoenix-GALV in our competitive repopulation assay in the baboon. The purpose of these studies was not to determine a single factor potentially affecting differences between cell lines but, rather, to compare the different conditioned media from PG13 and Phoenix-GALV for their ability to transduce and maintain hematopoietic repopulating cells. Three animals were transplanted with transduced CD34 + cells to compare vectors derived from Phoenix-GALV with vectors derived from PG13. In all three animals, transduction efficiency into hematopoietic repopulating cells was higher with the
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Phoenix-GALV-derived vector than with the PG13-derived vector. This difference was statistically significant.
In a second series of three baboons, we performed a competitive repopulation assay in which we compared the oncoretroviral vector produced by the Phoenix-GALV producer cell line to a more recently described lentiviral vector construct. Lentiviral vectors may be superior to oncoretroviral vectors due to their ability to integrate into non-dividing cells. 10, 11 Based on the rather low transduction efficiency of long-term repopulating cells with shorter transduction protocols and minimal growth factor support during transduction, 21, 22 (also Horn, manuscript submitted), we decided to use the three-day transduction protocol optimized for oncoretroviral vectors. We used IL-3, IL-6, SCF, Flt3-L, G-CSF and MGDF for prestimulation and transduction based on our recently published and encouraging results with this growth-factor combination. 16 In all three animals, preinfusion transduction efficiency into progenitor cells was higher with the Phoenix-GALV-derived vector than with the lentiviral vector. In vivo transduction efficiency in repopulating cells with the Phoenix-GALV-derived vector was up to 60% early after transplant and then plateaued after two to three months at levels of approximately 20-30% for two of the animals and around 5% for the third animal. Transduction with a lentiviral vector in a three-day protocol in the presence of multiple recombinant growth factors did not markedly improve the transduction efficiencies obtained with these vectors in shorter transduction protocols or with less cytokine support. [21] [22] [23] Other research groups have also reported low gene transfer levels using lentiviral vectors in non-human primate transplant models. 21, 22 These findings are in contrast to the high transduction efficiencies obtained with these vectors in human NOD/SCID repopulating cells. 12, 13, 24 A species-specific difference in susceptibility to lentiviral transduction between humans and non-human primates such as baboons and rhesus macaques has been considered but would not explain the high transduction efficiency into baboon CFUs 23 and baboon NOD/SCID repopulating cells. 25 An alternative explanation would be that this difference is a result of assaying different cell populations in the NOD/SCID xenotransplant system versus the autologous transplant setting. We are currently investigating these different possibilities.
Many different growth factor combinations have been used for oncoretroviral transduction of HSC, attempting to maintain a balance between sufficient stimulation of HSC to allow for vector integration and maintenance of HSC to ensure engraftment of transduced cells. 1, 4, 9, 14, 21, 22, 26, 27 The addition of IL-3, IL-6 and Flt3-L to the growth factor combination in the second set of animals (comparison between Phoenix-GALV-derived vectors and lentiviral vectors) resulted in a higher expansion rate and slightly higher pretransplant gene transfer rates using Phoenix-GALV-derived vectors compared to the first set of animals (Phoenix-GALV vs. We also compared the frequency of transgene-expressing leukocytes in the peripheral blood and in the bone marrow. No significant differences between the percentage of transgeneexpressing cells in bone marrow and peripheral blood were detected at any time point ( Figure 5 ). This is consistent with the findings reported by Sellers et al. 36 Thus, we did not find evidence for a block in differentiation or a specific immune rejection of mature cells in our study as had previously been suggested by other investigators.
37,38
To ensure that the improvement in gene transfer with the human-derived producer cell line was not a baboon-specific effect, we compared Phoenix-GALV-derived and PG13-derived vectors for their ability to transduce primary human CD34-enriched cells from G-CSF mobilized peripheral blood. Phoenix-GALV-derived vectors led to significantly higher transduction rates than PG13-derived vectors. It is noteworthy that both vectors were 3 to 5-fold more efficient in transducing human cells than baboon cells, which suggests that even higher gene transfer into long-term repopulating cells in humans could be achieved with this vector system.
In conclusion, our data show highly efficient transduction of non-human primate hematopoietic repopulating cells and sustained multilineage engraftment of transduced cells using GALV-pseudotype retroviral vectors produced by a human packaging cell line.
Transduction efficiency into short-term repopulating cells was up to 60%, with levels up to 20-30% at 3 months posttransplant and later. Importantly, transduction efficiencies into human CD34-enriched cells with vectors produced by the human producer cell line Phoenix-GALV were significantly higher than with PG13-derived vectors, suggesting that Phoenix-GALVderived vectors may also result in more efficient gene transfer into human hematopoietic stem cells. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
